SCHEMBL4657106

SCHEMBL4657106

CCOC(=O)c1cnn2c(-c3cccc(NC(=O)c4ccc(OC)c(Cl)c4)c3)ccnc12

nearest known ligand 0.80

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRAF P15056 15/20 0.80
PIM1 P11309 3/20 0.54
MAPK13 O15264 2/20 0.54
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
MAPT P10636 1/20 0.49
RAB9A P51151 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
GSK3A P49840 2/20 0.49
DAPK3 O43293 1/20 0.49
AKT1 P31749 1/20 0.49
MAPK9 P45984 1/20 0.49
NEK2 P51955 1/20 0.49
PIM3 Q86V86 1/20 0.49
PLK3 Q9H4B4 1/20 0.49
LIMK1 P53667 1/20 0.49
EPHA2 P29317 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4656054 0.92 BRAF (0.83) BRAFPIM1MAPK13GSK3ALIMK1
SCHEMBL4655849 0.91 BRAF (0.75) BRAFPIM1MAPK13MAPTGSK3A
SCHEMBL4655936 0.89 BRAF (0.77) BRAFPIM1MAPK13GSK3ALIMK1
SCHEMBL4656916 0.89 BRAF (1.00) BRAFPIM1MAPK13
SCHEMBL4655831 0.88 BRAF (0.78) BRAFPIM1MAPK13GSK3ALIMK1
SCHEMBL4657095 0.88 BRAF (0.76) BRAFPIM1MAPK13GSK3ALIMK1
SCHEMBL4657212 0.87 BRAF (0.84) BRAFPIM1MAPK13GSK3ADAPK3
SCHEMBL4656955 0.86 BRAF (1.00) BRAF
SCHEMBL4656020 0.86 BRAF (0.80) BRAFPIM1MAPK13GSK3ALIMK1
SCHEMBL4763004 0.86 BRAF (0.80) BRAFPIM1MAPK13GSK3AAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070219186-A1 Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof WYETH (US) 2007-09-20 US claimed
EP-1996594-A2 PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF Wyeth a Corporation of the State of Delaware (US) 2008-12-03 EP disclosed
WO-2007109093-A2 PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF WYETH (US) 2007-09-27 WO disclosed
US-20070219186-A1 Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof WYETH (US) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219186-A1 Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof DPYD, TYMP, TYMS BRAF 289/4885PIM1 1136/4885MAPK13 3288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.